JP2021527649A5 - - Google Patents

Info

Publication number
JP2021527649A5
JP2021527649A5 JP2020569831A JP2020569831A JP2021527649A5 JP 2021527649 A5 JP2021527649 A5 JP 2021527649A5 JP 2020569831 A JP2020569831 A JP 2020569831A JP 2020569831 A JP2020569831 A JP 2020569831A JP 2021527649 A5 JP2021527649 A5 JP 2021527649A5
Authority
JP
Japan
Prior art keywords
sequence
composition according
staufen1
modulator
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037355 external-priority patent/WO2019241734A1/en
Publication of JP2021527649A publication Critical patent/JP2021527649A/ja
Publication of JP2021527649A5 publication Critical patent/JP2021527649A5/ja
Priority to JP2024088206A priority Critical patent/JP2024123017A/ja
Pending legal-status Critical Current

Links

JP2020569831A 2018-06-14 2019-06-14 Ｓｔａｕｆｅｎ１調節剤および関連する方法 Pending JP2021527649A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024088206A JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685269P 2018-06-14 2018-06-14
US62/685,269 2018-06-14
PCT/US2019/037355 WO2019241734A1 (en) 2018-06-14 2019-06-14 Staufen1 regulating agents and associated methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024088206A Division JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Publications (2)

Publication Number Publication Date
JP2021527649A JP2021527649A (ja) 2021-10-14
JP2021527649A5 true JP2021527649A5 (enExample) 2022-06-14

Family

ID=68842359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020569831A Pending JP2021527649A (ja) 2018-06-14 2019-06-14 Ｓｔａｕｆｅｎ１調節剤および関連する方法
JP2024088206A Pending JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024088206A Pending JP2024123017A (ja) 2018-06-14 2024-05-30 Ｓｔａｕｆｅｎ１調節剤および関連する方法

Country Status (4)

Country Link
US (2) US11946046B2 (enExample)
EP (1) EP3807291A4 (enExample)
JP (2) JP2021527649A (enExample)
WO (1) WO2019241734A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102867A1 (en) * 2022-11-08 2024-05-16 University Of Utah Research Foundation Staufen-1 modulating agents, compositions, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
WO2006039399A2 (en) 2004-09-29 2006-04-13 University Of Rochester Staufen 1 (stau1) - mediated mrna decay
WO2009143371A2 (en) * 2008-05-21 2009-11-26 Intradigm Corporation COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
US9206479B2 (en) * 2011-02-09 2015-12-08 University Of Rochester Methods and compositions related to Staufen 1 binding sites formed by duplexing Alu elements
WO2013034684A1 (en) 2011-09-07 2013-03-14 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Strategies for prevention and/or treatment of diseases based on cd40 silencing
US10513701B2 (en) * 2015-03-25 2019-12-24 Università Degli Studi Di Trento RNA interference mediated therapy for neurodegenerative diseases
US11723912B2 (en) 2016-12-08 2023-08-15 University Of Utah Research Foundation Staufen1 agents and associated methods
EP3664816A4 (en) * 2017-08-08 2021-05-19 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES

Similar Documents

Publication Publication Date Title
JP7406793B2 (ja) ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
CN108136206B (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
CN102171342B (zh) 杜兴肌营养不良中有效的外显子(44)跳跃方法及相关手段
JP2024045199A5 (enExample)
JP2022544412A5 (enExample)
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
JP2022528487A (ja) Ｃ９ｏｒｆ７２のオリゴヌクレオチドベースの調節
US9290759B2 (en) Optimized miRNA constructs
JP2009537129A (ja) エキソンスキッピングを誘発する為の手段及び方法
US20220143197A1 (en) siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
CN111918968A (zh) Micro-RNA 22的抑制剂
EP4058152A1 (en) Oligonucleotide interference treatments of prostate cancer
CN119365598A (zh) 用于治疗单基因神经发育障碍的组合物和方法
US9217149B2 (en) Pharmaceutical composition for treating cancer
JP2021527649A5 (enExample)
WO2020185651A2 (en) Compositions and methods for treating huntington's disease
US20250179497A1 (en) Use of dinucleotide repeat rnas to treat cancer
JP2006514546A (ja) Ｂｃｌ−２を標的とする抑制性オリゴヌクレオチド
US20240417733A1 (en) Tis-l targeting antiviral antisense oligonucleotide with ability to inhibit viral replication of sars-cov-2
Gulam et al. Antisense therapy and its application in biopharmaceutical research: past, present and future
EP4608980A1 (en) Compositions and methods for anti-sense oligonucleotide (aso) treatment of huntington's disease
KR101888104B1 (ko) MET 엑손 14 스키핑 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2025507279A5 (enExample)
WO2024186688A2 (en) Compositions and methods for delivery of low dose effector agents